Illumina, Inc. (NASDAQ: ILMN) ‘has chosen seven genomics companies to participate in the third funding cycle of the global Illumina Accelerator. This global company creation accelerator focuses on partnering with entrepreneurs to build breakthrough startups operating in the field of genomics. The programme invested in 4 startups at the 3rd funding cycle of Illumina Accelerator Cambridge, UK, and 3 startups at the 13th funding cycle of Illumina Accelerator San Francisco Bay Area.
Founded in 2020, BixBio is working towards unlocking the potential of diverse genetic data to advance the sector of precision medicine by using proprietary AI platform in the curation and establishment of large genetic data sets. The biotech startup was founded by James Ross and Tyronne McCrindle.
Participants to the accelerator can receive seed investment funding, access Illumina sequencing and reagents, etc in addition to business guidance, genomics expertise, and a fully operational lab space in close proximity to Ilumina’s Cambridge UK and San Francisco Bay Area campuses.
Ventrueburn reports that BixBio will spend the next 6 months in Cambridge where it shall benefit from the accelerator’s expertise networks and global reach. In addition, BixBio had previously received funding from One Bio Venture Studio.
Other winners at the Illumina Cambridge were EpiCombi.AI Limited, Genegoggle Sp. z o.o, and NewStem Ltd. At the Ilummina Accelerator SF Bay Area, the winners were ImYoo Inc. Solena Ag, Inc, and Yali Biosciences Inc.
To find out more about the Illumina Accelerator or to participate in the next global funding cycle, apply on the website by 1st October, 2021.
Illumina Accelerator welcomes seven diverse #genomic startups to its third global funding cycle.
— Illumina (@illumina) September 15, 2021